{"id":"de-escalated-dual-antiplatelet-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Recurrent myocardial infarction"},{"rate":null,"effect":"Bleeding complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic strategy involves shortening the period of dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) or using lower doses compared to standard regimens. The approach aims to balance the prevention of stent thrombosis and recurrent ischemic events against the increased bleeding complications associated with prolonged dual therapy, particularly in patients at high bleeding risk.","oneSentence":"De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:13.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with percutaneous coronary intervention"},{"name":"Stable coronary artery disease with stent placement in high bleeding risk patients"}]},"trialDetails":[{"nctId":"NCT05380063","phase":"PHASE4","title":"Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-02-14","conditions":"Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy","enrollment":2300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["De-escalation"],"phase":"marketed","status":"active","brandName":"De-escalated Dual Antiplatelet Therapy","genericName":"De-escalated Dual Antiplatelet Therapy","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection. Used for Acute coronary syndrome with percutaneous coronary intervention, Stable coronary artery disease with stent placement in high bleeding risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}